LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
15 March 2017 07:00GMT LYNPARZA PHASE III SOLO-2 DATA DEMONSTRATE PROGRESSION-FREE SURVIVAL BENEFIT IN BRCA-MUTATED OVARIAN CANCER AS MAINTENANCE THERAPY Lynparza reduced risk of disease progression by 70% with an investigator-assessed progression-free survival of 19.1 months vs 5.5 months with placebo Blinded independent central review showed impressive progression-free survival of 30.2 months vs 5.5 months with placebo Lynparza tablets demonstrated a safety profile generally consistent with previous studies, including a low incidence of haematological toxicity AstraZeneca